For example, the prevalence of BRAF mutations, which promote tumor growth and angiogenesis alone, is not an indicator of treatment success; the BRAF inhibitor vemurafenib was effective in treating melanoma but not colorectal cancer, despite both having a high frequency of BRAF mutations [38]. The gene discussed is BRAF; the disease is colorectal cancer.